[go: up one dir, main page]

CL2019002190A1 - Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984) - Google Patents

Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984)

Info

Publication number
CL2019002190A1
CL2019002190A1 CL2019002190A CL2019002190A CL2019002190A1 CL 2019002190 A1 CL2019002190 A1 CL 2019002190A1 CL 2019002190 A CL2019002190 A CL 2019002190A CL 2019002190 A CL2019002190 A CL 2019002190A CL 2019002190 A1 CL2019002190 A1 CL 2019002190A1
Authority
CL
Chile
Prior art keywords
therapeutic protein
viscosity
concentration
antibody
reduction
Prior art date
Application number
CL2019002190A
Other languages
English (en)
Inventor
Christopher James Sloey
Sekhar Kanapuram
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54427875&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2019002190(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CL2019002190A1 publication Critical patent/CL2019002190A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE PROPORCIONA UN MÉTODO PARA REDUCIR LA VISCOSIDAD DE UNA FORMULACIÓN FARMACÉUTICA QUE UTILIZA UNA CONCENTRACIÓN DE REDUCCIÓN DE LA VISCOSIDAD DE UN EXCIPIENTE SELECCIONADO DEL GRUPO QUE CONSISTE DE LA N-ACETIL ARGININA, N-ACETIL LISINA, N-ACETIL PROLINA Y MEZCLAS DE LOS MISMOS EN COMBINACIÓN CON UNA PROTEÍNA TERAPÉUTICA. TAMBIÉN SE PROPORCIONA UNA FORMULACIÓN FARMACÉUTICA ESTABLE.
CL2019002190A 2014-10-23 2019-08-02 Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984) CL2019002190A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462067637P 2014-10-23 2014-10-23

Publications (1)

Publication Number Publication Date
CL2019002190A1 true CL2019002190A1 (es) 2019-11-22

Family

ID=54427875

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2017000984A CL2017000984A1 (es) 2014-10-23 2017-04-20 Reducción de la viscosidad de formulaciones farmacéuticas
CL2019002190A CL2019002190A1 (es) 2014-10-23 2019-08-02 Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2017000984A CL2017000984A1 (es) 2014-10-23 2017-04-20 Reducción de la viscosidad de formulaciones farmacéuticas

Country Status (17)

Country Link
US (3) US11813328B2 (es)
EP (2) EP3209332B1 (es)
JP (3) JP2017531682A (es)
KR (1) KR102534017B1 (es)
CN (2) CN114569716A (es)
AU (2) AU2015335743B2 (es)
BR (1) BR112017008125B1 (es)
CA (1) CA2964786C (es)
CL (2) CL2017000984A1 (es)
EA (3) EA033444B1 (es)
ES (1) ES2964713T3 (es)
IL (2) IL287947B2 (es)
MA (1) MA54716A (es)
MX (2) MX388858B (es)
SG (1) SG11201703152RA (es)
WO (1) WO2016065181A1 (es)
ZA (1) ZA201702762B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA54716A (fr) 2014-10-23 2021-11-17 Amgen Inc Réduction de la viscosité de formulations pharmaceutiques
MA46466A (fr) 2016-10-06 2019-08-14 Amgen Inc Formulations pharmaceutiques de protéines à viscosité réduite
JP7377596B2 (ja) * 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
US12257343B2 (en) 2017-04-28 2025-03-25 Amgen Inc. Excipients to reduce the viscosity of antibody formulations and formulation compositions
AU2018258676B2 (en) * 2017-04-28 2024-09-19 Amgen Inc. N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides
EP3624846B1 (en) 2017-05-16 2024-08-07 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity including a combination of nicotinic acid and tryoptophan
EP4424362A3 (en) 2017-06-16 2024-11-27 Zealand Pharma A/S Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
JP6577683B2 (ja) * 2017-09-22 2019-09-18 旭化成ファーマ株式会社 安定性に優れるテリパラチド含有液状医薬組成物
WO2019106206A1 (en) 2017-12-01 2019-06-06 Fyb 202 Project Gmbh Stable, low viscosity, high concentration liquid formulations of an anti-il-12/23p40 antibody
JP2021529800A (ja) 2018-07-05 2021-11-04 バイエル アクチェンゲゼルシャフトＢａｙｅｒ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗ＦＸＩａ抗体のための新規な安定した高濃度製剤
IL280880B2 (en) 2018-08-27 2025-04-01 Regeneron Pharma Using Raman Spectroscopy in Downstream Purification
EP3628683A1 (en) * 2018-09-28 2020-04-01 Zealand Pharma A/S Formulations of glucagon-like-peptide-2 (glp-2) analogues
WO2020219550A1 (en) * 2019-04-23 2020-10-29 Amgen Inc. The use of low molecular weight polyvinylpyrrolidone (pvp) to reduce viscosity of high concentration protein formulations
IL295042A (en) * 2020-02-13 2022-09-01 Amgen Inc Formulations of human anti-tslp antibodies and methods of treating inflammatory disease
KR102746418B1 (ko) * 2020-12-03 2024-12-26 동국대학교 산학협력단 N-아세틸-l-아르기닌을 포함하는 단백질 응집 억제용 조성물
KR20220126654A (ko) * 2021-03-09 2022-09-16 (주)지아이이노베이션 IgE Fc 수용체의 알파 서브유닛의 세포외 도메인을 포함하는 융합단백질의 제형
EP4319795A4 (en) * 2021-04-09 2025-03-05 Avantor Performance Materials, LLC Performance-enhancing excipients and methods of reducing viscosity and increasing stability of biologic formulations
WO2025175164A1 (en) * 2024-02-16 2025-08-21 Regeneron Pharmaceuticals, Inc. Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078997A (en) 1988-07-13 1992-01-07 Cetus Corporation Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
US5955448A (en) 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
AU1519399A (en) 1997-11-07 1999-05-31 Chiron Corporation Compositions providing for increased igf-i solubility
US6767892B1 (en) * 1997-11-07 2004-07-27 Chrion Corporation Compositions providing for increased IGF-I solubility
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6159485A (en) * 1999-01-08 2000-12-12 Yugenic Limited Partnership N-acetyl aldosamines, n-acetylamino acids and related n-acetyl compounds and their topical use
CA2403962C (en) 2000-03-31 2009-12-15 Kirin Beer Kabushiki Kaisha Powdery preparation for transmucosal administration comprising a medicine of high molecular weight and exhibiting an improved storage stability
PL209928B1 (pl) 2000-11-07 2011-11-30 Novartis Vaccines & Diagnostic Kompozycja farmaceutyczna zawierająca biologicznie aktywny IFN-β i mannitol, wstępnie napełniona strzykawka zawierająca tę kompozycję oraz sposób wytwarzania preparatu IFN-β
IL160358A0 (en) 2001-08-23 2004-07-25 Genmab As Human antibodies specific for interleukin 15 (il-15)
US20030180287A1 (en) 2002-02-27 2003-09-25 Immunex Corporation Polypeptide formulation
AU2003293543A1 (en) 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
CA2512174A1 (en) 2003-01-30 2004-08-12 Christian B. Allan Anti-integrin .alpha..nu..beta.3 antibody formulations and uses thereof
DK1610820T4 (da) * 2003-04-04 2013-11-04 Genentech Inc Høj-koncentration antistof- og proteinformuleringer
US8084032B2 (en) 2004-01-21 2011-12-27 Ajinomoto Co., Inc. Purification method which prevents denaturation of an antibody
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
EP1841455A1 (en) 2005-01-24 2007-10-10 Amgen Inc. Humanized anti-amyloid antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
WO2007074880A1 (ja) * 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha 抗体含有安定化製剤
CN101426527A (zh) * 2006-02-03 2009-05-06 米迪缪尼有限公司 蛋白质制剂
GB0603683D0 (en) 2006-02-23 2006-04-05 Novartis Ag Organic compounds
CA2651453C (en) 2006-05-11 2014-10-14 Isis Pharmaceuticals, Inc. 5'-modified bicyclic nucleic acid analogs
KR20090088950A (ko) 2006-12-14 2009-08-20 쉐링 코포레이션 가공된 항-ｔｓｌｐ 항체
WO2008155365A1 (en) 2007-06-20 2008-12-24 Irm Llc Methods and compositions for treating allergic diseases
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
TWI661833B (zh) * 2007-11-30 2019-06-11 百慕達商艾伯維生物技術有限責任公司 蛋白質調配物及製造其之方法
NZ621174A (en) * 2008-01-15 2015-09-25 Abbvie Deutschland Powdered protein compositions and methods of making same
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
JP2011067202A (ja) 2009-08-31 2011-04-07 Sanyo Chem Ind Ltd タンパク質水溶液の安定化剤、この安定化剤を含有するタンパク質水溶液及びタンパク質の安定化方法
WO2011060922A1 (en) * 2009-11-17 2011-05-26 Ipsen Pharma S.A.S. Formulation for hgh and rhigf-1 combination
AU2011212440B2 (en) 2010-02-04 2015-01-22 Csl Behring Ag Immunoglobulin preparation
WO2011104381A2 (en) * 2010-02-26 2011-09-01 Novo Nordisk A/S Stable antibody containing compositions
US20130171128A1 (en) 2010-03-02 2013-07-04 Amgen Inc. Reducing viscosity of pharmaceutical formulations
JP2013525484A (ja) * 2010-05-03 2013-06-20 ジェネンテック， インコーポレイテッド タンパク質含有製剤の粘度を低減させるために有用な組成物及び方法
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
JP6176849B2 (ja) 2011-07-19 2017-08-09 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
CA2951856A1 (en) * 2011-10-28 2013-05-02 Integritybio Inc. Protein formulations containing amino acids
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
EP2863951A1 (en) 2012-06-12 2015-04-29 Boehringer Ingelheim International GmbH Pharmaceutical formulation for a therapeutic antibody
US20150004174A1 (en) 2013-06-28 2015-01-01 Amgen Inc. Methods for treating homozygous familial hypercholesterolemia
TWI694836B (zh) 2014-05-16 2020-06-01 英商葛蘭素史克智慧財產管理有限公司 抗體調配物
MA54716A (fr) 2014-10-23 2021-11-17 Amgen Inc Réduction de la viscosité de formulations pharmaceutiques
CA2968915A1 (en) 2014-12-03 2016-06-09 Csl Behring Ag Pharmaceutical product with increased stability comprising immunoglobulins
KR102551269B1 (ko) 2016-09-29 2023-07-05 암젠 인크 저-점도 항원 결합 단백질 및 이의 제조 방법
MA46466A (fr) 2016-10-06 2019-08-14 Amgen Inc Formulations pharmaceutiques de protéines à viscosité réduite
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法

Also Published As

Publication number Publication date
MX388858B (es) 2025-03-20
JP2020037559A (ja) 2020-03-12
IL287947B1 (en) 2024-04-01
MX2017005243A (es) 2017-08-18
CA2964786C (en) 2023-10-17
AU2015335743A1 (en) 2017-05-04
EP3909611B1 (en) 2023-08-30
CN107206070B (zh) 2022-01-18
IL251726A0 (en) 2017-06-29
MX2021015789A (es) 2022-01-27
IL287947A (en) 2022-01-01
EP3209332B1 (en) 2021-05-26
WO2016065181A1 (en) 2016-04-28
KR102534017B1 (ko) 2023-05-19
CN107206070A (zh) 2017-09-26
ZA201702762B (en) 2022-12-21
SG11201703152RA (en) 2017-05-30
IL251726B (en) 2021-12-01
JP2017531682A (ja) 2017-10-26
BR112017008125B1 (pt) 2023-11-21
US20250345421A1 (en) 2025-11-13
AU2021200990B2 (en) 2023-02-16
EA201991447A1 (ru) 2019-11-29
EA202191513A1 (ru) 2021-11-30
MA54716A (fr) 2021-11-17
US12318447B2 (en) 2025-06-03
US11813328B2 (en) 2023-11-14
EA033444B1 (ru) 2019-10-31
AU2021200990A1 (en) 2021-03-11
CN114569716A (zh) 2022-06-03
EP3209332A1 (en) 2017-08-30
EA038462B1 (ru) 2021-08-31
JP2022009223A (ja) 2022-01-14
US20240066124A1 (en) 2024-02-29
IL287947B2 (en) 2024-08-01
AU2015335743B2 (en) 2020-12-24
JP7411615B2 (ja) 2024-01-11
KR20170071518A (ko) 2017-06-23
CA2964786A1 (en) 2016-04-28
BR112017008125A2 (pt) 2018-06-19
CL2017000984A1 (es) 2018-01-05
JP6965321B2 (ja) 2021-11-10
US20170333559A1 (en) 2017-11-23
EP3909611A1 (en) 2021-11-17
ES2964713T3 (es) 2024-04-09
EA201790787A1 (ru) 2017-08-31

Similar Documents

Publication Publication Date Title
CL2019002190A1 (es) Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984)
CY1125697T1 (el) Σταθερες, υδατικες φαρμακοτεχνικες μορφες αντισωματων
CL2019000431A1 (es) Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos. (divisional solicitud 201700814)
DOP2018000297A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
EA201890530A1 (ru) Конъюгаты антитела к dll3 и лекарственного средства и способы их применения
CL2016001604A1 (es) “compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de quinasas axl y c-met; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
BR112015020389A2 (pt) compostos carbazol úteis como inibidores de bromodomínio
DOP2015000108A (es) Compuestos de pirrolopirimidina como inhibidores de quinasas
CL2016002148A1 (es) Derivados de fenilen-1,5-diamina 2,4-disustituidos y aplicaciones de los mismos, y composiciones farmacéuticas y composiciones farmacéuticamente aceptables preparadas a partir de los mismos.
CR20150228A (es) Inhibidores de la tirosina-quinasa de bruton
CR20160203A (es) Inhibidores de tirosina cinasa de bruton
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
BR112015021888A8 (pt) inibidores de dna-pk, seus usos e composição farmacêutica
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
AR098168A1 (es) Formulación estable de insulina glulisina
EA201692292A1 (ru) Соединения и композиции для стимулирования хондрогенеза
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
CL2015002692A1 (es) Novedosos compuestos de bencenosulfonamida, método para sintetizarlos y uso de los compuestos en medicina y en cosméticos.
MX2020007760A (es) Composiciones y metodos para mejorar la biodisponibilidad de 5-hidroxitriptofano.
EA201591717A1 (ru) Твердые формы гидрохлорида вемурафениба
EA201990093A1 (ru) Двухкомпонентная композиция
EA201892157A1 (ru) Фосфаплатиновые жидкие составы
BR112015028302A2 (pt) formulação de pastilha de nicotina
MX2016014740A (es) Un metodo para el tratamiento de trastornos del movimiento con befiradol.